CG ONCOLOGY INC (CGON)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for CGON
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| CGON | Chairman of the Board; Chairman and Chief Executive Officer | 35 | ["Founding Member of Ally Bridge Group","managed fund’s portfolio companies from January 2013 to July 2015","served on the IP Commercialization Strategy Committee at Moffitt Cancer Center since November 2017","served on the board of directors of Chunghwa Chemical Synthesis & Biotech since 2022","board of directors of Allied Industrial Corp., Ltd. from 2016 to 2023","M.S. in Biotechnology from Johns Hopkins University","B.A. in Biology from University of Pennsylvania"] | ["IP Commercialization Strategy Committee","compensation committee","audit committee"] | 2026 |
Biography sourced from the proxy statement filing.
Arthur Kuan has served as Chairman and Chief Executive Officer of the Company since its inception in 2017, and as Chairman since December 2023. As a Founding Member of Ally Bridge Group, a global healthcare-focused investment platform, Mr. Kuan played a role in managing the fund's portfolio companies from January 2013 to July 2015. Mr. Kuan also served on the IP Commercialization Strategy Committee at Moffitt Cancer Center from November 2017 to January 2024. Previously, Mr. Kuan was a member of Themes Investment Partners, a Private Equity fund based in Hong Kong, where he played a central role in coordinating cross-border technology transfer and regulatory submissions for portfolio companies. Mr. Kuan began his career in an operational role at Dinova Capital, a Shanghai-based, medical technology incubator fund, evaluating medical device investment opportunities. Mr. Kuan has served on the board of directors of Chunghwa Chemical Synthesis & Biotech (TPEX: 1762), a Taiwanese manufacturer and distributor of chemical synthetic products and biotechnology products, since 2022, where he serves on its compensation committee and audit committee. From 2016 to 2023, he served on the board of directors of Allied Industrial Corp., Ltd. (TPEX: 4702), a leading supplier of disperse dyestuff. Mr. Kuan received his M.S. in Biotechnology from Johns Hopkins University and his B.A. in Biology from University of Pennsylvania. Mr. Kuan's knowledge of our business and experience investing in a number of biopharmaceutical companies contributed to our Board's conclusion that he should serve as a director of our Company.